News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Scancell Signs Antibody Licence Agreement with Cancer Research Technology



8/10/2010 8:04:12 AM

NOTTINGHAM, England--(BUSINESS WIRE)--Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, and Cancer Research Technology Ltd (‘CRT’) - Cancer Research UK’s commercialisation and development arm - today announce that they have signed an agreement under which Scancell has been granted a licence to use a human antibody known as 105AD7.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES